Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors
暂无分享,去创建一个
M. Lemmon | K. Ferguson | M A Lemmon | K M Ferguson | P J Darling | M J Mohan | T L Macatee | T. Macatee | P. Darling | Mohita J. Mohan | M. Mohan | Paul J. Darling
[1] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[2] Yosef Yarden,et al. Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.
[3] M. Sliwkowski,et al. Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.
[4] M. Waterfield,et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. , 1989, The EMBO journal.
[5] Y. Yarden,et al. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.
[6] H. P. Fell,et al. HER4-mediated Biological and Biochemical Properties in NIH 3T3 Cells , 1996, The Journal of Biological Chemistry.
[7] J. Schlessinger,et al. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. , 1988, The EMBO journal.
[8] Y. Yarden,et al. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.
[9] C. R. Middaugh,et al. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. , 1992, Analytical biochemistry.
[10] A. Ullrich,et al. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. , 1991, The Journal of biological chemistry.
[11] Y. Yarden,et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase , 1999, Oncogene.
[12] Y. Yarden,et al. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. , 1990, Biochemistry.
[13] A. Thomason,et al. Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2 (*) , 1996, The Journal of Biological Chemistry.
[14] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[15] M. Greene,et al. Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.
[16] Xin-Yuan Fu,et al. Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation , 1999, The Journal of cell biology.
[17] Y. Yarden,et al. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. , 1987, Biochemistry.
[18] M. O’Connor-McCourt,et al. The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant. , 1994, European journal of biochemistry.
[19] Pedro Cuatrecasas,et al. Local aggregation of hormone–receptor complexes is required for activation by epidermal growth factor , 1979, Nature.
[20] T. Arakawa,et al. Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*) , 1995, The Journal of Biological Chemistry.
[21] I. Lax,et al. Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. , 1993, Biochemistry.
[22] H. Jd,et al. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. , 1999 .
[23] D. Goeddel,et al. Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.
[24] A. Ullrich,et al. Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells , 1990, Molecular and cellular biology.
[25] J. Schlessinger. SH2/SH3 signaling proteins. , 1994, Current opinion in genetics & development.
[26] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[27] T. Pawson,et al. SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.
[28] M. Klagsbrun,et al. The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4* , 1996, The Journal of Biological Chemistry.
[29] J. Schlessinger,et al. Regulation of signal transduction and signal diversity by receptor oligomerization. , 1994, Trends in biochemical sciences.
[30] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[31] M. Sliwkowski,et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.
[32] D. Engelman,et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.
[33] D. Stern,et al. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.
[34] T. van Raaij,et al. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.
[35] L. Cantley,et al. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.
[36] W. Dougall,et al. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Sliwkowski,et al. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4 , 1998, FEBS letters.
[38] C. Cantor,et al. Biophysical Chemistry: Part II: Techniques for the Study of Biological Structure and Function , 1980 .
[39] A. Ullrich,et al. Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. , 1992, The Journal of biological chemistry.
[40] C DeLisi,et al. Interaction between proteins localized in membranes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[41] C. Betzel,et al. The secreted form of the epidermal growth factor receptor. Characterization and crystallization of the receptor-ligand complex. , 1990, The Journal of biological chemistry.
[42] M. Eisenstein,et al. Bivalence of EGF‐like ligands drives the ErbB signaling network , 1997, The EMBO journal.
[43] P. Wyatt. Light scattering and the absolute characterization of macromolecules , 1993 .
[44] I. Friedberg,et al. Secondary Dimerization between Members of the Epidermal Growth Factor Receptor Family* , 1997, The Journal of Biological Chemistry.
[45] S. Hubbard,et al. Autoregulatory Mechanisms in Protein-tyrosine Kinases* , 1998, The Journal of Biological Chemistry.
[46] M. Weber,et al. An Incomplete Program of Cellular Tyrosine Phosphorylations Induced by Kinase-defective Epidermal Growth Factor Receptors (*) , 1995, The Journal of Biological Chemistry.
[47] A. Ullrich,et al. Growth factor signaling by receptor tyrosine kinases , 1992, Neuron.
[48] R. Epstein,et al. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. , 1998, The Biochemical journal.
[49] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[50] A. Ullrich,et al. Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain. , 1991, The Journal of biological chemistry.
[51] D. Stern,et al. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation , 1999, Oncogene.